Rubin Lubomirov

8PUBLICATIONS
13CO-AUTHORS
Predictive and prognostic markersCancer geneticsToxicology (incl. clinical toxicology)Metabolomic chemistryCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Mar 27, 2025
CYP3A Genotype Is Associated With Variability in the Exposure and Clearance of the Novel Oncogenic Transcription Inhibitor Lurbinectedin.

Rubin Lubomirov, Laura Pérez-Ramos, Salvador Fudio

|Jan 08, 2025
Description and Modeling of Relevant Demographic and Laboratory Variables in a Large Oncology Cohort to Generate Virtual Populations.

Laura Pérez-Ramos, Laura Ibarra-Gómez, Rubin Lubomirov

|Apr 26, 2024
Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug-Drug Interaction Study.

Irene Moreno, Tatiana Hernández, Emiliano Calvo

|Mar 30, 2023
Quantitative determination of lurbinectedin, its unbound fraction and its metabolites in human plasma utilizing ultra-performance LC-MS/MS.

Nicholas King, Soledad Garcia-Martinez, Eider Alcaraz

|Aug 27, 2022
Anti-cancer drug combinations approved by US FDA from 2011 to 2021: main design features of clinical trials and role of pharmacokinetics.

Salvador Fudio, Alvaro Sellers, Laura Pérez Ramos

|Nov 05, 2021
Integrated exposure-response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer.

Carlos Fernández-Teruel, Salvador Fudio, Rubin Lubomirov

Pageof 2

Frequent Collaborators

6 joint publications

Salvador Fudio

3 joint publications

Carlos Fernandez-Teruel

2 joint publications

Eduardo Asín-Prieto

1 joint publications

Ignacio Gonzalez